Isatuximab, lenalidomide, dexamethasone and bortezomib in transplant-ineligible multiple myeloma: the randomized phase 3 BENEFIT trialXavier Leleu, Amine Kasmi, Aurore Perrot et al.|Nature Medicine|2024Cited by 109
Ibrutinib as a treatment of hematologic autoimmune disorders in patients with indolent B‐cell lymphomaAdrien Daniel, Louis Terriou, David Ghez et al.|European Journal Of Haematology|2022Cited by 8